Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Total Liabilities: 2021-2024

Historic Total Liabilities for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $28.9 million.

  • Amylyx Pharmaceuticals' Total Liabilities fell 43.60% to $30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.7 million, marking a year-over-year decrease of 43.60%. This contributed to the annual value of $28.9 million for FY2024, which is 65.64% down from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Total Liabilities of $28.9 million as of FY2024, which was down 65.64% from $84.0 million recorded in FY2023.
  • In the past 5 years, Amylyx Pharmaceuticals' Total Liabilities ranged from a high of $84.0 million in FY2023 and a low of $17.4 million during FY2021.
  • Over the past 3 years, Amylyx Pharmaceuticals' median Total Liabilities value was $50.8 million (recorded in 2022), while the average stood at $54.6 million.
  • As far as peak fluctuations go, Amylyx Pharmaceuticals' Total Liabilities surged by 191.70% in 2022, and later plummeted by 65.64% in 2024.
  • Amylyx Pharmaceuticals' Total Liabilities (Yearly) stood at $17.4 million in 2021, then soared by 191.70% to $50.8 million in 2022, then soared by 65.25% to $84.0 million in 2023, then slumped by 65.64% to $28.9 million in 2024.